BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kafi R, Fisher GJ, Quan T, Shao Y, Wang R, Voorhees JJ, Kang S. UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol. 2004;140:1322-1324. [PMID: 15545539 DOI: 10.1001/archderm.140.11.1322] [Cited by in Crossref: 48] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Nisar MF, Parsons KS, Bian CX, Zhong JL. UVA irradiation induced heme oxygenase-1: a novel phototherapy for morphea. Photochem Photobiol. 2014;91:210-220. [PMID: 25207998 DOI: 10.1111/php.12342] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
2 Chopra T, Kandukurti K, Shah S, Ahmed R, Panesar M. Understanding nephrogenic systemic fibrosis. Int J Nephrol. 2012;2012:912189. [PMID: 23193473 DOI: 10.1155/2012/912189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
3 Scheinfeld N. Nephrogenic fibrosing dermopathy: a comprehensive review for the dermatologist. Am J Clin Dermatol 2006;7:237-47. [PMID: 16901184 DOI: 10.2165/00128071-200607040-00005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
4 Rombold S, Lobisch K, Katzer K, Grazziotin TC, Ring J, Eberlein B. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol Photoimmunol Photomed 2008;24:19-23. [PMID: 18201353 DOI: 10.1111/j.1600-0781.2008.00328.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
5 Linfert DR, Schell JO, Fine DM. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Treatment of Nephrogenic Systemic Fibrosis: Limited Options but Hope for the Future: TREATMENT OF NSF. Seminars in Dialysis 2008;21:155-9. [DOI: 10.1111/j.1525-139x.2007.00407.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 2008;21:123-8. [PMID: 18226008 DOI: 10.1111/j.1525-139X.2007.00399.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 10] [Article Influence: 4.2] [Reference Citation Analysis]
7 Krous HF, Breisch E, Chadwick AE, Pinckney L, Malicki DM, Benador N. Nephrogenic Systemic Fibrosis with Multiorgan Involvement in a Teenage Male after Lymphoma, Ewing's Sarcoma, End-Stage Renal Disease, and Hemodialysis. Pediatr Dev Pathol 2007;10:395-402. [DOI: 10.2350/06-05-0093.1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
8 Boin F, Hummers LK. Scleroderma-like fibrosing disorders. Rheum Dis Clin North Am 2008;34:199-220; ix. [PMID: 18329541 DOI: 10.1016/j.rdc.2007.11.001] [Cited by in Crossref: 81] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
9 Zhang R, Rose WN. Photopheresis Provides Significant Long-Lasting Benefit in Nephrogenic Systemic Fibrosis. Case Rep Dermatol Med. 2017;2017:3240287. [PMID: 28695022 DOI: 10.1155/2017/3240287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Swaminathan S, Leung N. Nephrogenic fibrosing dermopathy: lessons from the past. Int J Dermatol 2006;45:639-41. [PMID: 16796618 DOI: 10.1111/j.1365-4632.2006.02837.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
11 Teske NM, Jacobe HT. Phototherapy for sclerosing skin conditions. Clin Dermatol 2016;34:614-22. [PMID: 27638441 DOI: 10.1016/j.clindermatol.2016.05.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
12 Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, Simpson K, Roditi GH. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007;245:168-175. [PMID: 17704357 DOI: 10.1148/radiol.2451070353] [Cited by in Crossref: 247] [Cited by in F6Publishing: 166] [Article Influence: 17.6] [Reference Citation Analysis]
13 Heymann WR. Nephrogenic systemic fibrosis—The beginning of the end? Journal of the American Academy of Dermatology 2007;57:171-2. [DOI: 10.1016/j.jaad.2007.02.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Hellman RN. Gadolinium-induced nephrogenic systemic fibrosis. Semin Nephrol 2011;31:310-6. [PMID: 21784280 DOI: 10.1016/j.semnephrol.2011.05.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
15 Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol. 2008;66:191-199. [PMID: 18325705 DOI: 10.1016/j.ejrad.2008.01.016] [Cited by in Crossref: 89] [Cited by in F6Publishing: 67] [Article Influence: 6.8] [Reference Citation Analysis]
16 Tuchinda C, Kerr HA, Taylor CR, Jacobe H, Bergamo BM, Elmets C, Rivard J, Lim HW. UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States. Photoderm Photoimm Photomed 2006;22:247-53. [DOI: 10.1111/j.1600-0781.2006.00245.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
17 Penfield JG. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents. Pediatr Nephrol 2008;23:2121-9. [PMID: 18543004 DOI: 10.1007/s00467-008-0862-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
18 High WA. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Expert Review of Dermatology 2014;2:593-605. [DOI: 10.1586/17469872.2.5.593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
19 Gambichler T, Terras S, Kreuter A. Treatment regimens, protocols, dosage, and indications for UVA1 phototherapy: Facts and controversies. Clinics in Dermatology 2013;31:438-54. [DOI: 10.1016/j.clindermatol.2013.01.011] [Cited by in Crossref: 49] [Cited by in F6Publishing: 29] [Article Influence: 6.1] [Reference Citation Analysis]
20 Mazhar SM, Shiehmorteza M, Kohl CA, Middleton MS, Sirlin CB. Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging 2009;30:1313-22. [PMID: 19937937 DOI: 10.1002/jmri.21983] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
21 Mayr M, Burkhalter F, Bongartz G. Nephrogenic systemic fibrosis: Clinical spectrum of disease. J Magn Reson Imaging 2009;30:1289-97. [DOI: 10.1002/jmri.21975] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
22 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
23 Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Current Opinion in Rheumatology 2006;18:614-7. [DOI: 10.1097/01.bor.0000245725.94887.8d] [Cited by in Crossref: 121] [Cited by in F6Publishing: 87] [Article Influence: 8.1] [Reference Citation Analysis]
24 Penfield JG, Reilly RF. What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol. 2007;3:654-668. [PMID: 18033225 DOI: 10.1038/ncpneph0660] [Cited by in Crossref: 241] [Cited by in F6Publishing: 171] [Article Influence: 18.5] [Reference Citation Analysis]
25 Cowper SE. Nephrogenic Systemic Fibrosis: A Review and Exploration of the Role of Gadolinium. Advances in Dermatology 2007;23:131-54. [DOI: 10.1016/j.yadr.2007.07.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
26 York NR, Jacobe HT. UVA1 phototherapy: a review of mechanism and therapeutic application. Int J Dermatol 2010;49:623-30. [PMID: 20618465 DOI: 10.1111/j.1365-4632.2009.04427.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
27 Goddard DS, Magee CC, Lazar AJ, Miller DM. Nephrogenic fibrosing dermopathy with recurrence after allograft failure. Journal of the American Academy of Dermatology 2007;56:S109-11. [DOI: 10.1016/j.jaad.2006.04.061] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
28 Introcaso CE, Hivnor C, Cowper S, Werth VP. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: a case series of nine patients and review of the literature. Int J Dermatol. 2007;46:447-452. [PMID: 17472669 DOI: 10.1111/j.1365-4632.2007.03301.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
29 Bernstein EJ, Schmidt-lauber C, Kay J. Nephrogenic systemic fibrosis: A systemic fibrosing disease resulting from gadolinium exposure. Best Practice & Research Clinical Rheumatology 2012;26:489-503. [DOI: 10.1016/j.berh.2012.07.008] [Cited by in Crossref: 61] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
30 Leguit RJ, Raymakers RAP, Hebeda KM, Goldschmeding R. CCN2 (Cellular Communication Network factor 2) in the bone marrow microenvironment, normal and malignant hematopoiesis. J Cell Commun Signal 2021;15:25-56. [PMID: 33428075 DOI: 10.1007/s12079-020-00602-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
31 Mendichovszky IA, Marks SD, Simcock CM, Olsen OE. Gadolinium and nephrogenic systemic fibrosis: time to tighten practice. Pediatr Radiol. 2008;38:489-496; quiz 602-603. [PMID: 17943276 DOI: 10.1007/s00247-007-0633-8] [Cited by in Crossref: 71] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
32 Kurban MS, Boueiz A, Kibbi AG. Cutaneous manifestations of chronic kidney disease. Clin Dermatol. 2008;26:255-264. [PMID: 18640522 DOI: 10.1016/j.clindermatol.2007.10.017] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
33 Saxena SK, Sharma M, Patel M, Oreopoulos D. Nephrogenic systemic fibrosis: an emerging entity. Int Urol Nephrol 2008;40:715-24. [PMID: 18418727 DOI: 10.1007/s11255-008-9361-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
34 Plamondon I, Samson C, Watters AK, Bégin LR, Côté J, Déziel C, Quérin S. La fibrose systémique néphrogénique: nouveau coup dur pour les insuffisants rénaux. Néphrologie & Thérapeutique 2007;3:152-6. [DOI: 10.1016/j.nephro.2007.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
35 Auron A, Shao L, Warady BA. Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol 2006;21:1307-11. [DOI: 10.1007/s00467-006-0174-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]